Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen NEUPOGEN (filgrastim by Year

Name: Amgen NEUPOGEN (filgrastim by Year (AMGN)
Creator: Amgen

NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Worldwide product sales ($M) ($M)

Quarterly Annual

Amgen NEUPOGEN (filgrastim: $144M in FY2022, down 14.3% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.

Latest, FY2022

144

Period ended Dec 31, 2022

Change on a year earlier

-14.3%

168 in FY2021

History

8 years

Since FY2015

Sources

Documents cited below

Where the FY2022 figure comes from

“|| NEUPOGEN ® | 87 | 57 | 144 | 168 | (14%)”

Source: Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Worldwide product sales ($M) ($M)	Year on year	Source
FY2022	Dec 31, 2022	144	-14.3%	Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
FY2021	Dec 31, 2021	168	-25.3%	Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
FY2020	Dec 31, 2020	225	-14.8%	Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
FY2019	Dec 31, 2019	264	-27.7%	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
FY2018	Dec 31, 2018	365	-33.5%	Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗
FY2017	Dec 31, 2017	549	-28.2%	Form 10-K (filed 2018-02-13) ↗
FY2016	Dec 31, 2016	765	-27.1%	Form 10-K (filed 2018-02-13) ↗
FY2015	Dec 31, 2015	1,049	–	Form 10-K (filed 2018-02-13) ↗

Breakdown

What makes up NEUPOGEN (filgrastim

Cite this data

StockData. (2026). Amgen NEUPOGEN (filgrastim ($M), annual FY2015–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neupogen-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.